Investment Strategy Analysis for AI Software and Hardware
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Source: NASDAQ.COM
- AI Investment Trends: HSBC analyst Stephen Bersey highlights that 2026 will mark the kickoff for monetization in AI software, predicting that software will capture the largest long-term value in the AI market, suggesting investors should diversify across both software and hardware stocks to navigate market uncertainties.
- Microsoft vs. Google Competition: Despite Google Workspace offering free tools, Microsoft's enterprise software sales rose 16% to $34 billion in the latest quarter, demonstrating its strong competitive position in enterprise software and reflecting the ongoing demand for highly reliable software among businesses.
- Nvidia Financial Highlights: Nvidia's recent Q4 fiscal 2026 report revealed a 75% surge in data center revenue to $62.3 billion, with adjusted earnings per share increasing by 82% to $1.62, surpassing Wall Street expectations, indicating that further growth is likely ahead.
- Hardware Investment Outlook: AMD's deal with Meta Platforms, valued at over $100 billion for 6 gigawatts of data center processors, underscores the accelerating investment in AI hardware, with data center spending projected to reach between $3 trillion and $4 trillion by 2030, showcasing the long-term potential of the hardware market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVDA
Wall Street analysts forecast NVDA stock price to rise
41 Analyst Rating
39 Buy
1 Hold
1 Sell
Strong Buy
Current: 204.650
Low
200.00
Averages
264.97
High
352.00
Current: 204.650
Low
200.00
Averages
264.97
High
352.00
About NVDA
NVIDIA Corporation is an artificial intelligence (AI) infrastructure company. The Company is engaged in accelerated computing to help solve the challenging computational problems. Its segments include Compute & Networking and Graphics. The Compute & Networking segment includes its Data Center accelerated computing and networking platforms and AI solutions and software, and automotive platforms and autonomous and electric vehicle solutions, including software. The Graphics segment includes GeForce GPUs for gaming and personal computers (PCs), and Quadro/NVIDIA RTX GPUs for enterprise workstation graphics. Its technology stack includes the foundational NVIDIA CUDA development platform that runs on all NVIDIA GPUs, as well as hundreds of domain-specific software libraries, frameworks, algorithms, software development kits (SDKs), and application programming interfaces (APIs). Its platforms address four markets, which include Data Center, Gaming, Professional Visualization, and Automotive.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
United States Oil Fund Returns Just 22% Over a Decade
- Return Analysis: Over the past decade, the United States Oil Fund (USO) has only achieved a total return of 22.46%, while crude oil prices surged from $16.55 to $114.84, indicating that investors failed to effectively capture price movements, reflecting the fund's structural costs.
- Futures Roll Decay: USO rolls its front-month NYMEX WTI futures contracts monthly, and when the futures curve is in contango, the fund sells the cheaper expiring contract and buys the more expensive next one, leading to a monthly bleed in net asset value (NAV) even when spot crude prices remain flat.
- Tax Complexity: As a commodity pool limited partnership, USO investors receive a K-1 tax form, with long-term gains taxed at 60% and short-term gains at 40%, regardless of holding period, which adds unexpected accounting costs for investors.
- Market Risk Warning: As of June 17, 2026, USO is up 65.17% year-to-date, but analysts warn that if the Strait of Hormuz reopens, crude futures could quickly decline, erasing USO's yield advantage, with a 14.94% drop in the past week already observed.
See More
Nvidia Launches Vera CPU Platform, Tapping into $200 Billion Market
- Market Opportunity Expansion: Nvidia's newly launched Vera CPU platform is purpose-built for emerging agentic AI technology, expected to unlock a $200 billion market, significantly enhancing its competitive position in AI infrastructure.
- Comprehensive Product Offering: The Vera CPU, combined with Nvidia's GPUs, networking, and CUDA software, creates a complete ecosystem that allows the company to capture incremental value from each AI deployment, thereby increasing customer loyalty.
- Optimistic Revenue Projections: CFO Colette Kress stated that total CPU revenue is expected to reach nearly $20 billion this year, indicating that the Vera CPU is already being viewed as a strong alternative for AI infrastructure build-outs.
- Accelerated Strategic Transformation: The introduction of the Vera CPU marks Nvidia's evolution from a GPU supplier to a full-stack AI infrastructure provider, enhancing its market share and customer attachment rates in AI data centers.
See More
Eli Lilly and Twist Bioscience: AI in Drug Development
- AI Innovation at Eli Lilly: Eli Lilly collaborates with OpenAI for drug discovery and establishes an AI co-innovation lab with Nvidia, aiming to accelerate drug development and enhance its position in the competitive pharmaceutical market.
- Strong Financial Performance: In Q1 2026, Eli Lilly reported a 56% revenue increase to $19.8 billion and a 168% surge in net income to $7.4 billion, indicating improved operational efficiency and promising future growth potential despite its large scale.
- Market Dynamics for Twist Bioscience: Twist Bioscience's revenue rose 19% to $110.7 million in Q2 2026, marking 13 consecutive quarters of growth, although net losses widened to $44 million, highlighting challenges faced during expansion.
- Partnership with Amazon: Twist Bioscience has become a key lab in Amazon's Bio Discovery platform, leveraging AI to design drugs and collaborate with real-world partners, which is expected to create new business growth opportunities and enhance its market competitiveness.
See More
Nvidia and AMD Compete in the AI Revolution
- Significant Revenue Growth: Nvidia and AMD reported revenue increases of 85% and 38% respectively in the latest quarter, showcasing their strong performance in the AI sector and further solidifying their market positions.
- Market Leadership: Nvidia maintains its lead in AI chip design due to its first-mover advantage in the data center GPU market, consistently updating its products, and is expected to continue dominating the GPU market.
- CPU Market Competition: While AMD holds a leadership position in the CPU market, Nvidia's introduction of its first standalone data center CPU indicates its intent to expand in the AI space, potentially gaining an edge in future competition.
- Robotics Technology Outlook: Nvidia's full-stack solutions in robotics have attracted over 2 million developers, positioning the company to capitalize on a $40 trillion market opportunity, while AMD demonstrates strong potential in medical and industrial robotics through its adaptive system-on-chip solutions.
See More
Nvidia and AMD Compete in the AI Era
- Significant Revenue Growth: Nvidia and AMD reported revenue increases of 85% and 38% respectively in the latest quarter, reflecting strong demand in the AI market and driving both companies' stock prices up over 300% in the past three years, underscoring their leadership in the industry.
- GPU Market Competition: Nvidia has maintained its lead in the AI sector due to its early entry and continuous innovation in the data center GPU market, while AMD, despite its CPU dominance, has yet to surpass Nvidia in the GPU space, highlighting the intense competition.
- CPU Market Potential: As AI technology evolves, the importance of CPUs is increasing; Nvidia has launched its first standalone data center CPU and plans to release a superchip integrating GPU and CPU in the second half of the year, indicating its intent to capture market share in CPUs, although AMD still holds an advantage.
- Robotics Technology Outlook: Nvidia's full-stack solutions in robotics position it favorably for future AI growth, particularly with its Jetson Thor robotics computer used by over 2 million developers, while AMD showcases potential in surgical robots through its adaptive system-on-chip solutions, reflecting differing strategies in this high-growth market.
See More
Eli Lilly and Twist Bioscience's AI Drug Development Strategies
- AI Innovation at Eli Lilly: Eli Lilly collaborates with OpenAI for drug discovery and establishes an AI co-innovation lab with Nvidia to accelerate the identification of promising drug molecules, resulting in a 56% revenue increase to $19.8 billion and a 168% rise in net income to $7.4 billion in Q1 2026, indicating significant efficiency improvements.
- New Drug Potential: Lilly's newly approved weight-loss pill, Foundayo, which can be taken at any time, replaces injections and is expected to attract a broader patient base, further expanding market share and enhancing the company's position in the rapidly growing weight-loss drug market.
- Twist's Growth Risks: Twist Bioscience's stock has risen over 136% in the past year, despite a 26% decline over the past five years, with Q2 2026 revenue up 19% to $110.7 million, marking 13 consecutive quarters of revenue growth, although net loss widened to $44 million primarily due to a $7.2 million settlement.
- Partnership with Amazon: Twist's collaboration with Amazon positions it as a key lab in the Amazon Bio Discovery platform, leveraging AI to design drugs and develop them with real-world partners, highlighting the company's critical role in AI-driven drug development despite facing higher uncertainty.
See More
United States Oil Fund Returns Just 22% Over a Decade
- Return Analysis: Over the past decade, the United States Oil Fund (USO) has only achieved a total return of 22.46%, while crude oil prices surged from $16.55 to $114.84, indicating that investors failed to effectively capture price movements, reflecting the fund's structural costs.
- Futures Roll Decay: USO rolls its front-month NYMEX WTI futures contracts monthly, and when the futures curve is in contango, the fund sells the cheaper expiring contract and buys the more expensive next one, leading to a monthly bleed in net asset value (NAV) even when spot crude prices remain flat.
- Tax Complexity: As a commodity pool limited partnership, USO investors receive a K-1 tax form, with long-term gains taxed at 60% and short-term gains at 40%, regardless of holding period, which adds unexpected accounting costs for investors.
- Market Risk Warning: As of June 17, 2026, USO is up 65.17% year-to-date, but analysts warn that if the Strait of Hormuz reopens, crude futures could quickly decline, erasing USO's yield advantage, with a 14.94% drop in the past week already observed.
See More
Nvidia Launches Vera CPU Platform, Tapping into $200 Billion Market
- Market Opportunity Expansion: Nvidia's newly launched Vera CPU platform is purpose-built for emerging agentic AI technology, expected to unlock a $200 billion market, significantly enhancing its competitive position in AI infrastructure.
- Comprehensive Product Offering: The Vera CPU, combined with Nvidia's GPUs, networking, and CUDA software, creates a complete ecosystem that allows the company to capture incremental value from each AI deployment, thereby increasing customer loyalty.
- Optimistic Revenue Projections: CFO Colette Kress stated that total CPU revenue is expected to reach nearly $20 billion this year, indicating that the Vera CPU is already being viewed as a strong alternative for AI infrastructure build-outs.
- Accelerated Strategic Transformation: The introduction of the Vera CPU marks Nvidia's evolution from a GPU supplier to a full-stack AI infrastructure provider, enhancing its market share and customer attachment rates in AI data centers.
See More
Eli Lilly and Twist Bioscience: AI in Drug Development
- AI Innovation at Eli Lilly: Eli Lilly collaborates with OpenAI for drug discovery and establishes an AI co-innovation lab with Nvidia, aiming to accelerate drug development and enhance its position in the competitive pharmaceutical market.
- Strong Financial Performance: In Q1 2026, Eli Lilly reported a 56% revenue increase to $19.8 billion and a 168% surge in net income to $7.4 billion, indicating improved operational efficiency and promising future growth potential despite its large scale.
- Market Dynamics for Twist Bioscience: Twist Bioscience's revenue rose 19% to $110.7 million in Q2 2026, marking 13 consecutive quarters of growth, although net losses widened to $44 million, highlighting challenges faced during expansion.
- Partnership with Amazon: Twist Bioscience has become a key lab in Amazon's Bio Discovery platform, leveraging AI to design drugs and collaborate with real-world partners, which is expected to create new business growth opportunities and enhance its market competitiveness.
See More
Nvidia and AMD Compete in the AI Revolution
- Significant Revenue Growth: Nvidia and AMD reported revenue increases of 85% and 38% respectively in the latest quarter, showcasing their strong performance in the AI sector and further solidifying their market positions.
- Market Leadership: Nvidia maintains its lead in AI chip design due to its first-mover advantage in the data center GPU market, consistently updating its products, and is expected to continue dominating the GPU market.
- CPU Market Competition: While AMD holds a leadership position in the CPU market, Nvidia's introduction of its first standalone data center CPU indicates its intent to expand in the AI space, potentially gaining an edge in future competition.
- Robotics Technology Outlook: Nvidia's full-stack solutions in robotics have attracted over 2 million developers, positioning the company to capitalize on a $40 trillion market opportunity, while AMD demonstrates strong potential in medical and industrial robotics through its adaptive system-on-chip solutions.
See More
Nvidia and AMD Compete in the AI Era
- Significant Revenue Growth: Nvidia and AMD reported revenue increases of 85% and 38% respectively in the latest quarter, reflecting strong demand in the AI market and driving both companies' stock prices up over 300% in the past three years, underscoring their leadership in the industry.
- GPU Market Competition: Nvidia has maintained its lead in the AI sector due to its early entry and continuous innovation in the data center GPU market, while AMD, despite its CPU dominance, has yet to surpass Nvidia in the GPU space, highlighting the intense competition.
- CPU Market Potential: As AI technology evolves, the importance of CPUs is increasing; Nvidia has launched its first standalone data center CPU and plans to release a superchip integrating GPU and CPU in the second half of the year, indicating its intent to capture market share in CPUs, although AMD still holds an advantage.
- Robotics Technology Outlook: Nvidia's full-stack solutions in robotics position it favorably for future AI growth, particularly with its Jetson Thor robotics computer used by over 2 million developers, while AMD showcases potential in surgical robots through its adaptive system-on-chip solutions, reflecting differing strategies in this high-growth market.
See More
Eli Lilly and Twist Bioscience's AI Drug Development Strategies
- AI Innovation at Eli Lilly: Eli Lilly collaborates with OpenAI for drug discovery and establishes an AI co-innovation lab with Nvidia to accelerate the identification of promising drug molecules, resulting in a 56% revenue increase to $19.8 billion and a 168% rise in net income to $7.4 billion in Q1 2026, indicating significant efficiency improvements.
- New Drug Potential: Lilly's newly approved weight-loss pill, Foundayo, which can be taken at any time, replaces injections and is expected to attract a broader patient base, further expanding market share and enhancing the company's position in the rapidly growing weight-loss drug market.
- Twist's Growth Risks: Twist Bioscience's stock has risen over 136% in the past year, despite a 26% decline over the past five years, with Q2 2026 revenue up 19% to $110.7 million, marking 13 consecutive quarters of revenue growth, although net loss widened to $44 million primarily due to a $7.2 million settlement.
- Partnership with Amazon: Twist's collaboration with Amazon positions it as a key lab in the Amazon Bio Discovery platform, leveraging AI to design drugs and develop them with real-world partners, highlighting the company's critical role in AI-driven drug development despite facing higher uncertainty.
See More
